Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate

KAREN BRÄUTIGAM, KATHARINA MITZLAFF, LISA UEBEL, FRANK KÖSTER, STEPHAN POLACK, MASCHA PERVAN, GUNNAR STEINERT, ACHIM RODY and CORNELIA LIEDTKE
Anticancer Research June 2016, 36 (6) 2759-2766;
KAREN BRÄUTIGAM
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Karen.Braeutigam{at}uksh.de
KATHARINA MITZLAFF
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LISA UEBEL
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANK KÖSTER
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHAN POLACK
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASCHA PERVAN
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GUNNAR STEINERT
2Eisai GmbH, Frankfurt am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ACHIM RODY
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CORNELIA LIEDTKE
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 36 no. 6 2759-2766
PMID 
27272786

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received March 21, 2016
  • Revision received April 25, 2016
  • Accepted April 27, 2016
  • Published online June 6, 2016.

Copyright & Usage 
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. KAREN BRÄUTIGAM1⇑,
  2. KATHARINA MITZLAFF1,
  3. LISA UEBEL1,
  4. FRANK KÖSTER1,
  5. STEPHAN POLACK1,
  6. MASCHA PERVAN1,
  7. GUNNAR STEINERT2,
  8. ACHIM RODY1 and
  9. CORNELIA LIEDTKE1
  1. 1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany
  2. 2Eisai GmbH, Frankfurt am Main, Germany
  1. Correspondence to: Karen Bräutigam, Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany. E-mail: Karen.Braeutigam{at}uksh.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 10 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 36, Issue 6
June 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
KAREN BRÄUTIGAM, KATHARINA MITZLAFF, LISA UEBEL, FRANK KÖSTER, STEPHAN POLACK, MASCHA PERVAN, GUNNAR STEINERT, ACHIM RODY, CORNELIA LIEDTKE
Anticancer Research Jun 2016, 36 (6) 2759-2766;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
KAREN BRÄUTIGAM, KATHARINA MITZLAFF, LISA UEBEL, FRANK KÖSTER, STEPHAN POLACK, MASCHA PERVAN, GUNNAR STEINERT, ACHIM RODY, CORNELIA LIEDTKE
Anticancer Research Jun 2016, 36 (6) 2759-2766;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Integrating Mathematical Modeling with High-Throughput Imaging Explains How Polyploid Populations Behave in Nutrient-Sparse Environments
  • Invasion of homogeneous and polyploid populations in nutrient-limiting environments
  • Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines
  • Google Scholar

More in this TOC Section

  • Ginsenoside Rh4 Induces Apoptosis Through ROS-Mediated Fas Signaling in Human Nasopharyngeal Carcinoma NPC/HK1 Cells
  • Genome-wide Analysis Highlights rs4671908 and rs2238431 as Predictors of Survival in Nasopharyngeal Carcinoma
  • Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma
Show more Experimental Studies

Keywords

  • Triple-negative breast cancer
  • TNBC
  • subtypes
  • eribulin
  • cell lines
  • chemosensitivity
  • proliferation
  • apoptosis
  • migration
  • invasion
  • gene expression
  • malignant transformation
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire